|
|
Article: Takeda Pharmaceuticals North America Shares Early Stage Data on Ramelteon, Formerly Known as TAK-375.
- Article from:
- PR Newswire
- Article date:
- October 20, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO, Oct. 20 /PRNewswire/ -- Results from pre-clinical trials of ramelteon (formerly known as TAK-375), under development by Takeda Pharmaceuticals North America (TPNA) for transient and chronic insomnia, were presented today at the American Neurological Association's (ANA) annual meeting in San Francisco.
These studies examined the effects of various combinations of ramelteon, exogenous melatonin, and benzodiazepine, opiate, and ML-2 receptor agonists on sleeping behavior, learning abilities, memory, motor coordination and abuse potential in different animal models.
"We are excited about the continued development of ramelteon because in our ...